Martha W. den Hollander

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹Zr-Fresolimumab PET

Martha W. den Hollander, Frederike Bensch, Andor W.J.M. Glaudemans et al. · Journal of Nuclear Medicine · 2015 · 101 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

Rachel M. Hurley, Andrea E. Wahner Hendrickson, Daniel W. Visscher et al. · Gynecologic Oncology · 2019 · 74 citations · Full text

Medicine, Molecular Biology, Oncology +12

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study

Cyrillo G. Brahm, Martha W. den Hollander, Roelien H. Enting et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 32 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Diane A.J. van der Biessen, Jourik A. Gietema, Maja J.A. de Jonge et al. · Investigational New Drugs · 2018 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17

Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers

Martha W. den Hollander, Nico-Derk L. Westerink, Sjoukje Lubberts et al. · The Oncologist · 2016 · 11 citations · Full text

Medicine, Oncology, Radiology +17